Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Cessatech

12.32 DKK

+0.16 %

Less than 1K followers

CESSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.16 %
+4.41 %
+11.59 %
-16.30 %
+4.41 %
-0.24 %
+545.03 %
-
+14.24 %

Cessatech operates in the pharmaceutical industry. The company specializes in research and development of analgesic nasal sprays that are also used for the treatment of acute pain conditions in children. In addition to the main business, associated ancillary services and related products are also offered. The business is operated globally with the largest presence in the Nordic market. Cessatech was founded in 2020 and is headquartered in Copenhagen.

Read more
Market cap
228.86M DKK
Turnover
202.32K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release11/13/2025, 7:30 AM

Cessatech: Third Quarter Report Q3-2025

Cessatech
Regulatory press release10/31/2025, 12:00 PM

Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children

Cessatech
Regulatory press release8/21/2025, 6:30 AM

Cessatech: Second Quarter Report Q2-2025

Cessatech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release8/14/2025, 4:00 PM

Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children

Cessatech
Press release6/27/2025, 11:31 AM

Cessatech Q&A - June company presentation

Cessatech
Regulatory press release6/19/2025, 11:30 AM

Cessatech strengthens Executive Management with the promotion of Martin Juhl

Cessatech
Regulatory press release6/11/2025, 12:15 PM

Cessatech announce completion of the directed issue of shares

Cessatech
Regulatory press release5/28/2025, 8:30 PM

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch

Cessatech
Regulatory press release5/28/2025, 3:30 PM

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch

Cessatech
Regulatory press release5/28/2025, 3:15 PM

Cessatech announces positive top-line results from its final CT001 Study 0202

Cessatech
Regulatory press release5/15/2025, 6:30 AM

Cessatech: First Quarter Report Q1-2025

Cessatech
Regulatory press release4/30/2025, 1:45 PM

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001

Cessatech
Regulatory press release3/28/2025, 10:30 AM

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech
Regulatory press release3/12/2025, 7:30 AM

Cessatech: Annual General Meeting - 28 March 2025

Cessatech
Regulatory press release2/28/2025, 7:30 AM

Cessatech A/S publishes Annual Report for the fiscal year 2024

Cessatech
Regulatory press release2/4/2025, 10:30 AM

Cessatech receives positive Notified Body opinion under MDR for CT001

Cessatech
Regulatory press release12/23/2024, 11:00 AM

Cessatech updates the milestones for the coming year

Cessatech
Regulatory press release11/13/2024, 12:00 PM

Cessatech: Third Quarter Report Q3-2024

Cessatech
Regulatory press release10/16/2024, 8:00 AM

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

Cessatech
Regulatory press release9/2/2024, 8:00 AM

Cessatech and Proveca partnership - Q&A

Cessatech
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.